A Phase 2 interventional study of T-817MA-H and T-817MA-L in Alzheimer's Disease, sponsored by FUJIFILM Toyama Chemical Co., Ltd.. Completed at 50 sites in United States. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-02-26.
Sponsored by FUJIFILM Toyama Chemical Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,941 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 444 under way, 40 of them phase 3. Alzheimer Disease · United States.
Among the 1,941 studies in Alzheimer Disease with a site in United States, this one is the 189th largest by enrollment of the 1,610 interventional ones that give a count, is one of 54 that started in 2014, is one of 360 in phase 2, and was the 629th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →346 of the 1,941 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:
National Institute on Aging (NIA) · Sites in United States
Ages 55–110 · Healthy volunteers
National Institute on Aging (NIA) · Sites in United States
Ages 65–120 · Healthy volunteers
Prevention Research Consortium Corp. · Sites in United States
Ages 55+ · Healthy volunteers
Hoffmann-La Roche · Sites in United States, Australia, France and 2 more countries
Ages 50–90
University of Wisconsin, Madison · Sites in United States
Ages 60+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 55 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,941 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 371 · Phase 2 469 · Phase 3 230 · Phase 4 60
First in 1981; this study’s year is marked. 54 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 482 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 73 across the 1,610 interventional studies, 160 across the 309 observational. Of the 1,379 that completed or were terminated, 592 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
731 of 1,941 have an industry lead sponsor. The 10 most frequent:
FUJIFILM Toyama Chemical Co., Ltd. is the lead sponsor of 5 studies on the registry; none are open to participants now.
FUJIFILM Toyama Chemical Co., Ltd. has 2 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
164 of the studies in Alzheimer Disease with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT03860857Phase 3University of California, IrvineBiomarker Exploration in Aging, Cognition and Neurodegeneration | 2026-12-22 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
Add all 164 to your calendar (.ics) → With an account.
Among the 1,941 studies in Alzheimer Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective is to evaluate the efficacy of T-817MA as measured by ADAS-cog and ADCS-CGIC.
The secondary objectives are:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
224 mg T-817MA once daily for first 4 weeks and 448 mg T-817MA once daily for the following weeks.
Drug: T-817MA-H
224 mg T-817MA once daily
Drug: T-817MA-L
Placebo once daily
Drug: Placebo
224 mg or 448 mg T-817 MA once daily
224 mg T-817 MA once daily
Placebo
ADAS-cog Change From Baseline to Week 52
The ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale) is a structured scale that evaluates memory (word recall, word recognition), reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). Ratings of spoken language, language comprehension, word finding difficulty, and ability to remember test instructions are also obtained. The test is scored in terms of errors, with higher scores reflecting poorer performance and greater impairment. Scores can range from 0 (best) to 70 (worse).
Time frame: Baseline and 52 weeks
CGIC
The ADCS-CGIC (Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change) is a validated categorical measure of change in the patient's clinical condition between baseline and follow-up visits. It measures whether the effects of active treatment are substantial enough to be detected by a skilled and experienced clinician on the basis of a clinical interview and examination. It relies on both direct examination of the patient and an interview of the study partner. A skilled and experienced clinician who is blinded to treatment assignment rates the patient on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening). It is suggested that the instrument has distinct clinical utility in assessing change in AD clinical trials.
Time frame: 52 weeks
ADCS-ADL Change From Baseline to Week 52
The ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living) is a validated tool for assessing instrumental and basic activities of daily living based on a 23-item structured interview of the study partner. The scale has a range of 0 to 78, with lower scores indicating greater impairment.
Time frame: Baseline and 52 weeks
| Milestone | T-817MA-H | T-817MA-L | Placebo |
|---|---|---|---|
| Started | 158 | 166 | 158 |
| Completed | 120 | 117 | 140 |
| Not completed | 38 | 49 | 18 |
| Withdrew: Adverse event | 23 | 23 | 7 |
| Withdrew: Withdrawal by subject | 9 | 17 | 4 |
| Withdrew: Lost to follow-up | 2 | 3 | 1 |
| Withdrew: Death | 2 | 2 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 1 |
| Withdrew: Physician decision | 0 | 1 | 1 |
| Withdrew: Relocation etc. | 2 | 2 | 3 |
The ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale) is a structured scale that evaluates memory (word recall, word recognition), reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). Ratings of spoken language, language comprehension, word finding difficulty, and ability to remember test instructions are also obtained. The test is scored in terms of errors, with higher scores reflecting poorer performance and greater impairment. Scores can range from 0 (best) to 70 (worse).
| units on a scale | T-817MA-H | T-817MA-L | Placebo |
|---|---|---|---|
| ADAS-cog Change From Baseline to Week 52 | 7.08 ± 0.756 | 7.45 ± 0.756 | 7.91 ± 0.727 |
The ADCS-CGIC (Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change) is a validated categorical measure of change in the patient's clinical condition between baseline and follow-up visits. It measures whether the effects of active treatment are substantial enough to be detected by a skilled and experienced clinician on the basis of a clinical interview and examination. It relies on both direct examination of the patient and an interview of the study partner. A skilled and experienced clinician who is blinded to treatment assignment rates the patient on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening). It is suggested that the instrument has distinct clinical utility in assessing change in AD clinical trials.
| units on a scale | T-817MA-H | T-817MA-L | Placebo |
|---|---|---|---|
| CGIC | 5.25 ± 0.1 | 5.24 ± 0.1 | 5.22 ± 0.1 |
The ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living) is a validated tool for assessing instrumental and basic activities of daily living based on a 23-item structured interview of the study partner. The scale has a range of 0 to 78, with lower scores indicating greater impairment.
| units on a scale | T-817MA-H | T-817MA-L | Placebo |
|---|---|---|---|
| ADCS-ADL Change From Baseline to Week 52 | -10.01 ± 0.991 | -11.07 ± 0.992 | -11.29 ± 0.957 |
Collected over 52weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| T-817MA-H | 2/158 (1.3%) | 26/158 (16.5%) | 132/158 (83.5%) |
| T-817MA-L | 2/166 (1.2%) | 25/166 (15.1%) | 133/166 (80.1%) |
| Placebo | 0/158 (0%) | 20/158 (12.7%) | 119/158 (75.3%) |
| Event | T-817MA-H | T-817MA-L | Placebo |
|---|---|---|---|
| SyncopeNervous system disorders | 0/158 | 2/166 | 3/158 |
| DeliriumPsychiatric disorders | 3/158 | 1/166 | 1/158 |
| CellulitisInfections and infestations | 2/158 | 0/166 | 0/158 |
| Urinary Tract InfectionInfections and infestations | 2/158 | 1/166 | 1/158 |
| DehydrationMetabolism and nutrition disorders | 2/158 | 2/166 | 0/158 |
| Chest PainGeneral disorders | 0/158 | 2/166 | 1/158 |
| SepsisInfections and infestations | 0/158 | 2/166 | 0/158 |
| Anaemia MacrocyticBlood and lymphatic system disorders | 1/158 | 0/166 | 0/158 |
| Acute Myocardial InfarctionCardiac disorders | 0/158 | 0/166 | 1/158 |
| Atrial FibrillationCardiac disorders | 0/158 | 0/166 | 1/158 |
| Event | T-817MA-H | T-817MA-L | Placebo |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 49/158 | 34/166 | 20/158 |
| Urinary tract infectionInfections and infestations | 21/158 | 17/166 | 22/158 |
| FallInjury, poisoning and procedural complications | 12/158 | 14/166 | 17/158 |
| HeadacheNervous system disorders | 9/158 | 16/166 | 10/158 |
| AgitationPsychiatric disorders | 4/158 | 5/166 | 14/158 |
| NauseaGastrointestinal disorders | 9/158 | 13/166 | 6/158 |
| AnxietyPsychiatric disorders | 7/158 | 9/166 | 12/158 |
| DizzinessNervous system disorders | 11/158 | 7/166 | 3/158 |
| NasopharyngitisInfections and infestations | 4/158 | 4/166 | 9/158 |
| VomitingGastrointestinal disorders | 9/158 | 8/166 | 7/158 |
The overall numbers of baseline participants display patient numbers in the mITT population, the primary analysis population. The mITT population excludes patients who did not take any study drug or did not perform any efficacy evaluation post-baseline. Thus, the numbers are slightly difference from the ones in the participant flow.
| Age, Continuous(years) | T-817MA-H | T-817MA-L | Placebo | Total |
|---|---|---|---|---|
| Mean | 71.8 ± 7.8 | 71.9 ± 8.2 | 71.8 ± 7.5 | 71.9 ± 7.8 |
| Sex: Female, Male(Participants) | T-817MA-H | T-817MA-L | Placebo | Total |
|---|---|---|---|---|
| Female | 82 | 81 | 89 | 252 |
| Male | 72 | 78 | 67 | 217 |
| Race (NIH/OMB)(Participants) | T-817MA-H | T-817MA-L | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 3 | 3 | 2 | 8 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| Black or African American | 8 | 7 | 11 | 26 |
| White | 140 | 146 | 142 | 428 |
| More than one race | 0 | 1 | 1 | 2 |
| Unknown or Not Reported | 2 | 1 | 0 | 3 |
| ApoE4 genotype(Participants) | T-817MA-H | T-817MA-L | Placebo | Total |
|---|---|---|---|---|
| Non-carriers | 54 | 57 | 50 | 161 |
| Heterozygotes | 55 | 74 | 71 | 200 |
| Homozygotes | 32 | 21 | 27 | 80 |
| Unknown | 13 | 7 | 8 | 28 |
| MMSE(units on a scale) | T-817MA-H | T-817MA-L | Placebo | Total |
|---|---|---|---|---|
| Mean | 18.4 ± 3.9 | 18.2 ± 3.8 | 18.2 ± 3.8 | 18.3 ± 3.8 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Mar 2014, a primary completion of May 2017 and a completion of May 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2018, 1 year 3 months after primary completion. A results delay was requested in Feb 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: T-817 maleate
FUJIFILM Toyama Chemical Co., Ltd.